Send PM
Followers 1
Posts 70
Boards Moderated 0
Alias Born 03/12/2019

Re: None

Thursday, 05/12/2022 10:52:29 PM

Thursday, May 12, 2022 10:52:29 PM

Post# of 814
MAT2203 Update

“Fundamentally, we understand .. you have the potential for a broad reach.. for all invasive fungal infections, so everything here is about positioning this drug to optimize its potential in being the key agent in the treatment of all invasive fungal infections.

..higher outside of the U.S., so it was a necessary approach for us whether we were going to completely hold onto this asset ourselves and build a global franchise or respond to the interests, comments and questions of parties who are interested in taking this drug and commercializing and developing it outside the U.S., that we had those necessary inputs to be able to inform strategic discussions, so harmony is key.

FDA has been a great foundation. The EMA now has the full data package. We’ll engage in those discussions in the third and fourth quarter of this year with the idea that we do want total alignment here because it will help us and our partner to optimize the value of this drug.” (Jabbour)

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MTNB News